EMA Withdrawn: Ariclaim (duloxetine) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA withdrew Ariclaim (duloxetine) from the market in the Diabetic Neuropathies therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• Ariclaim (duloxetine)

Snippet

Status: Withdrawn. Therapeutic area: Diabetic Neuropathies. MAH: Eli Lilly Nederland B.V.. Decision date: 09/12/2016